Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy

Yu, Wennian; Sun, Guan; Li, Jun; Jiang, Xu; Wang, X

doi:10.1016/j.canlet.2019.02.048

Cited by 200 publications

(123 citation statements)

References 69 publications

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…Novel immunotherapeutic strategies that target immune checkpoint pathways by altering T cell receptor (TCR) signaling have revolutionized treatment options for all types of cancers. Several studies show that immune therapy can boost the outcome of chemotherapy, radiotherapy, and/or other targeted therapies [19][20][21]. The immunogenicity of BC and the applicability of immunogenic pathways to enhance the treatment outcome of BC patients were not explored much in earlier days.…”

Section: Introductionmentioning

confidence: 99%

Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models

Padmanabhan

Kheraldine

Meskin

et al. 2020

Cancers

View full text Add to dashboard Cite

Breast cancer is one of the major causes of mortality in women worldwide. The most aggressive breast cancer subtypes are human epidermal growth factor receptor-positive (HER2+) and triple-negative breast cancers. Therapies targeting HER2 receptors have significantly improved HER2+ breast cancer patient outcomes. However, several recent studies have pointed out the deficiency of existing treatment protocols in combatting disease relapse and improving response rates to treatment. Overriding the inherent actions of the immune system to detect and annihilate cancer via the immune checkpoint pathways is one of the important hallmarks of cancer. Thus, restoration of these pathways by various means of immunomodulation has shown beneficial effects in the management of various types of cancers, including breast. We herein review the recent progress in the management of HER2+ breast cancer via HER2-targeted therapies, and its association with the programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) axis. In order to link research in the areas of medicine and mathematics and point out specific opportunities for providing efficient theoretical analysis related to HER2+ breast cancer management, we also review mathematical models pertaining to the dynamics of HER2+ breast cancer and immune checkpoint inhibitors.

show abstract

Section: Introductionmentioning

confidence: 99%

Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models

Padmanabhan

Kheraldine

Meskin

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Other than that, thoracic irradiation in stage I–III disease is improving the prognosis, if implemented within 30 days of chemotherapy [58]. With regard to the ‘abscopal effect’, local irradiation and systemic chemotherapy in stage IV disease might promote the effect of concomitant immunotherapy with PD-1/PD-L1 inhibitors by inducing immunogenic cell death [59]. Hence, combination therapies of chemotherapy, irradiation and immunotherapy will be the focus of clinical research to further improve SCLC patients’ outcomes.…”

Section: Introductionmentioning

confidence: 99%

Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer

Schulze

Evers

Kerkhoff

et al. 2019

Cancers

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related deaths worldwide. With a focus on histology, there are two major subtypes: Non-small cell lung cancer (NSCLC) (the more frequent subtype), and small cell lung cancer (SCLC) (the more aggressive one). Even though SCLC, in general, is a chemosensitive malignancy, relapses following induction therapy are frequent. The standard of care treatment of SCLC consists of platinum-based chemotherapy in combination with etoposide that is subsequently enhanced by PD-L1-inhibiting atezolizumab in the extensive-stage disease, as the addition of immune-checkpoint inhibition yielded improved overall survival. Although there are promising molecular pathways with potential therapeutic impacts, targeted therapies are still not an integral part of routine treatment. Against this background, we evaluated current literature for potential new molecular candidates such as surface markers (e.g., DLL3, TROP-2 or CD56), apoptotic factors (e.g., BCL-2, BET), genetic alterations (e.g., CREBBP, NOTCH or PTEN) or vascular markers (e.g., VEGF, FGFR1 or CD13). Apart from these factors, the application of so-called ‘poly-(ADP)-ribose polymerases’ (PARP) inhibitors can influence tumor repair mechanisms and thus offer new perspectives for future treatment. Another promising therapeutic concept is the inhibition of ‘enhancer of zeste homolog 2’ (EZH2) in the loss of function of tumor suppressors or amplification of (proto-) oncogenes. Considering the poor prognosis of SCLC patients, new molecular pathways require further investigation to augment our therapeutic armamentarium in the future.

show abstract

“…Cancer remains a major cause of mortality and many of the therapies that have been used so far to fight it are very often ineffective and bring high degree of toxicity ( Puzanov et al, 2017 ). Until recently, cancer was routinely treated through surgical, chemotherapy and/or radiotherapy approaches ( Yu W.D. et al, 2019 ).…”

Section: Immunotherapy As a New Frontier In The Fight Against Cancermentioning

confidence: 99%

Microbiota and Cancer: The Emerging Beneficial Role of Bifidobacteria in Cancer Immunotherapy

et al. 2020

View full text Add to dashboard Cite

Many intestinal bacteria are believed to be involved in various inflammatory and immune processes that influence tumor etiology because of their metabolic properties and their ability to alter the microbiota homeostasis. Although many functions of the microbiota are still unclear, there is compelling experimental evidence showing that the intestinal microbiota is able to modulate carcinogenesis and the response to anticancer therapies, both in the intestinal tract and other body sites. Among the wide variety of gut-colonizing microorganisms, various species belonging to the Bifidobacterium genus are believed to elicit beneficial effects on human physiology and on the host-immune system. Recent findings, based on preclinical mouse models and on human clinical trials, have demonstrated the impact of gut commensals including bifidobacteria on the efficacy of tumor-targeting immunotherapy. Although the underlying molecular mechanisms remain obscure, bifidobacteria and other microorganisms have become a promising aid to immunotherapeutic procedures that are currently applied to treat cancer. The present review focuses on strategies to recruit the microbiome in order to enhance anticancer responses and develop therapies aimed at fighting the onset and progression of malignancies.

show abstract

Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy

Cited by 200 publications

References 69 publications

Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models

Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models

Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer

Microbiota and Cancer: The Emerging Beneficial Role of Bifidobacteria in Cancer Immunotherapy

Contact Info

Product

Resources

About